<DOC>
	<DOCNO>NCT00259064</DOCNO>
	<brief_summary>The purpose study determine addition Iressa Best Supportive Care treatment increase progression free survival chemo-na√Øve , poor performance status patient , stage IIIB IV NSCLC .</brief_summary>
	<brief_title>Iressa v BSC ( Best Supportive Care ) First Line NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC NSCLC locally advance ( Stage IIIB ) metastatic ( stage IV ) disease , amenable curative surgery radiotherapy Not suitable chemotherapy WHO Performance status 2 3 Newly diagnose CNS mets Less 4 week since completion radiotherapy persistence radiotherapy relate toxicity Other coexist malignancy ALT/AST great 5 x upper limit normal ANC le 1.0 x 109/L platelet less 100 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>